摘要
宫颈癌通常与高风险的人乳头状瘤病毒感染有关,而且在全世界导致女性癌症死亡的主要原因。在1990年代末,涌起 一大批以铂为基础的化学疗法的益处报道,但缺乏子宫癌临床试验。局部晚期和复发或者转移子宫癌更有效的治疗时临床亟需的。在分子肿瘤学领域,对于局部和晚期子宫癌应当不仅只看到传统疗法和放化疗。事实上致癌的因素,感染高危人乳头状瘤病毒和病毒性肿瘤蛋白表达是几乎所有的子宫癌所常见的,提供了独特的疾病控制机会。探索子宫癌的多样通路的开发和发展应用。第一次,最近晚期子宫癌患者通过目标药物,抗血管新生剂贝伐单抗,耐用完成反应后针对人乳头状瘤病毒过继转移CC患者T细胞疗法获得了增加的总体存活率。在这篇综述中,我们将总结了人乳头状瘤病毒的分子方面关注停止致癌过程的潜在目标,目前药物开发数据更新,并讨论挑战和未来前景。
关键词: 癌症,致癌,子宫颈,人乳头状瘤病毒,靶向治疗。
Current Cancer Drug Targets
Title:Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer
Volume: 16 Issue: 3
Author(s): A. Nogueira-Rodrigues, A.C. Melo, G. Werutsky, A.H.I. Garces and C.G.Ferreira
Affiliation:
关键词: 癌症,致癌,子宫颈,人乳头状瘤病毒,靶向治疗。
摘要: Cervical carcinomas are almost universally associated with high-risk human papillomavirus (HPV) infections, and are a leading cause of cancer death in women worldwide. Since the late 1990s, when a spate of studies reported the benefit of cisplatin-based chemotherapy, there had been a dearth of clinical trials in cervical cancer (CC). More effective therapies in locally advanced and recurrent or metastatic CC are an urgent clinical need. In the era of molecular oncology one should look beyond conventional chemoradiation and chemotherapy for locally advanced and advanced CC. The fact that the initiating oncogenic insult, infection with a high-risk HPV and viral oncoprotein expression is common to almost all CC offers unique opportunities for disease control. Diverse biologic pathways with an implication in the development and progression of CC are being explored. For the first time, increase in overall survival has recently been obtained for advanced CC patients with a target drug, the antiangiogenic agent bevacizumab, and durable complete responses after HPV-targeted adoptive T cell therapy in metastatic CC patients were achieved. In this review, we will summarize molecular aspects of HPV infection focusing on potential targets to stop the carcinogenic process, present updated drug development data, and discuss challenges and prospects for the future.
Export Options
About this article
Cite this article as:
A. Nogueira-Rodrigues, A.C. Melo, G. Werutsky, A.H.I. Garces and C.G.Ferreira , Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer, Current Cancer Drug Targets 2016; 16 (3) . https://dx.doi.org/10.2174/1568009616666151118115018
DOI https://dx.doi.org/10.2174/1568009616666151118115018 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry Understanding the Molecular Mechanisms of Betel miRNAs on Human Health
MicroRNA Monoclonal Antibodies: A Prospective and Retrospective View
Current Medicinal Chemistry Topical Targeting Therapies for Sexually Transmitted Diseases
Current Nanoscience Unknown Primary Squamous Cell Carcinoma of the Head and Neck
Current Cancer Therapy Reviews Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Non-Traditional Drug Targets: High Risk, High Reward
Current Gene Therapy A Machine Learning-based Self-risk Assessment Technique for Cervical Cancer
Current Bioinformatics Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Vitamin D Receptor is a Novel Drug Target for Ovarian Cancer Treatment
Current Cancer Drug Targets Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Current Drug Discovery Technologies The Possible Role of Infertility Drugs in Later Malignancy: A Review
Current Medicinal Chemistry P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets Spatio-Temporal Expression and Functional Analysis of miR-206 in Developing Orofacial Tissue
MicroRNA RNA Interference and Potential Applications
Current Topics in Medicinal Chemistry Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy